Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin
View abstract on PubMed
Summary
This summary is machine-generated.Achieving adequate anti-factor Xa levels during enoxaparin treatment for unstable angina/non-ST-segment-elevation myocardial infarction is crucial. Subtherapeutic anticoagulation levels are linked to increased 30-day mortality, emphasizing the need for therapeutic anti-Xa activity.
Area Of Science
- Cardiology
- Pharmacology
- Clinical Medicine
Background
- Low-molecular-weight heparin (LMWH) is a standard treatment for unstable angina (UA)/non-ST-segment-elevation myocardial infarction (NSTEMI).
- Previous studies have not established a clear link between LMWH anticoagulation levels and patient outcomes.
- This study investigates the relationship between anti-factor Xa activity and clinical outcomes in UA/NSTEMI patients.
Purpose Of The Study
- To determine if anticoagulation levels achieved with enoxaparin correlate with clinical outcomes in UA/NSTEMI patients.
- To assess the association between anti-factor Xa activity and 30-day mortality.
- To evaluate the predictive value of anti-factor Xa levels for bleeding complications.
Main Methods
- A cohort of 803 UA/NSTEMI patients treated with subcutaneous enoxaparin was analyzed.
- Patients were followed for 30 days post-treatment.
- Anti-factor Xa activity was measured, and its correlation with mortality and bleeding was assessed using univariate and multivariate analyses.
Main Results
- Subtherapeutic anti-factor Xa levels (<0.5 IU/mL) were associated with lower enoxaparin doses.
- Low anti-factor Xa levels (<0.5 IU/mL) significantly increased 30-day mortality by over threefold compared to therapeutic levels (0.5-1.2 IU/mL).
- Low anti-factor Xa activity was an independent predictor of mortality, comparable to factors like age and renal function. No association was found between anti-Xa levels and major bleeding.
Conclusions
- Subtherapeutic anti-factor Xa activity during enoxaparin therapy is independently linked to increased 30-day mortality in UA/NSTEMI patients.
- Maintaining therapeutic anti-factor Xa levels (≥0.5 IU/mL) is critical for improving survival in these patients.
- Monitoring anti-factor Xa activity may be essential for optimizing enoxaparin treatment efficacy and patient outcomes.